
KardiaMobile 6L is conditionally recommended for use in psychiatric services, as an option to measure cardiac QT interval for adults having or about to have antipsychotic medication

Read the [Health Technology Evaluation \(HTE10\)](#) to learn more about how our technology can support you and your patients.




We are proud to offer KardiaMobile 6L for use in psychiatric services, as an option to measure cardiac QT interval for adults having or about to have antipsychotic medication. This recommendation has the potential to improve care for service users and to help NHS services to ensure timely ECG testing is available for all while creating more efficient care pathways.

Our Technology

KardiaMobile is the most clinically validated, medical-grade personal ECG in the world. KardiaMobile is a CE-marked, FDA-cleared medical-grade personal ECG device. Our AI-driven technology can detect the most common arrhythmias— AF, bradycardia, and tachycardia— in just 30 seconds. Users receive instant analysis of their ECG right on their smartphone and can send to their clinician with the press of a button.

Our clinical enterprise solution, KardiaPro, connects with KardiaMobile 6L to enhance patient care and streamline ECG interpretation through remote patient monitoring. Patient ECG data is transmitted automatically from the Kardia app to your practice's KardiaPro portal. The Kardia system can also be integrated via KardiaPro into Electronic Health Records.



Highlights from the NICE Health Technology Evaluation (HTE10):

- KardiaMobile 6L has the potential to **improve care for service users** and to help the NHS create more efficient care pathways.
- Early access to the technology could help patients get **faster access to safe and effective antipsychotic treatment**.
- KardiaMobile 6L allows ECG recording with less need for undressing and **without using conductive stickers or gel**.
- Service users found KardiaMobile 6L **more comfortable and easier to use** than a 12-lead device
- KardiaMobile 6L was also **preferred for dignity and privacy**, and considered 12-lead ECG to be more intrusive.
- KardiaMobile 6L ECGs **can be recorded during a routine home visit** by a community health professional. This may **reduce stress and anxiety**.
- The committee recognised that it is important to offer QT interval measurement to people at a place and time they can attend and in a way that they feel comfortable.
- Access to less intrusive QT interval measurement with flexibility around the time and place of the appointment is **important to vulnerable patients**.
- Detecting cardiac abnormalities such as prolonged QT is important because antipsychotics can prolong the QT interval and lead to severe cardiac events.
- People taking antipsychotic medication may need to have tests for cardiac abnormalities before starting treatment and at regular intervals during treatment.
- Data sources suggested that it was **faster to use KardiaMobile 6L than the 12-lead device**.

What it means for you, the clinician?

- Potential improvement in care for service users and ability to **create more efficient care pathways**.
- Help patients get **faster access** to safe and effective antipsychotic treatment.
- **Improves accessibility and availability of** a convenient ECG solution with minimal training required.
- **Less preparation required** and no intrusive access needed - meaning less reluctance and anxiety to participation from the patient.
- Enhances flexibility of the ECG appointment, with fewer limitations to time and location.
- **Instant results**, anytime, anywhere.

What does this mean for AliveCor?

- This conditional recommendation **supports an unmet clinical need** - easier accessibility and availability of QT interval measurement in the psychiatric service setting.
- KardiaMobile 6L technology **supports our NHS services** to ensure timely ECG testing is available for all while creating more efficient care pathways as comfortable as possible for patients
- Alignment to our core mission: to save lives and **transform cardiology by delivering intelligent, highly-personalized heart data** to clinicians and patients anytime, anywhere.

To read the full report, please visit our resource hub at alivecor.co.uk/resource-hub.

Email sean.warren@alivecor.com for more information.

[View References](#)